Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: A Spanish group for research on sarcoma study

Journal of Clinical Oncology

Volumn 34, Issue 19, 2016, Pages 2294-2302

  Martin Broto, Javier ^a   Pousa, Antonio López ^b   De Las Peñ, Ramón ^e   Muro, Xavier García Del ^c   Gutierrez, Antonio ^f   Martinez Trufero, Javier ^h   Cruz, Josefina ⁱ   Alvarez, Rosa ^j   Cubedo, Ricardo ^k   Redondo, Andrés ^l   Maurel, Joan ^d   Carrasco, Juan A ^o   López Martin, José A ^m   Sala, Ángeles ^p   Meana, José Andrés ^q   Ramos, Rafael ^f   Martinez Serra, Jordi ^f   Lopez Guerrero, José A ^r   Sevilla, Isabel ^s   Balaña, Carmen ^t   Vaz, Ángeles ⁿ   De Juan, Ana ^p   Alemany, Regina ^g   Poveda, Andrés ^r   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e Hospital Provincial   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ HOSPITAL RAMÓN Y CAJAL   (Spain)

^o HOSPITAL XERAL CÍES   (Spain)

^p HOSPITAL DE BASURTO   (Spain)

^q University General Hospital   (Spain)

^r Valencian Autonomous Government   (Spain)

^s HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^t Insitut Catal d'Oncologia   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; FAS ANTIGEN; PROTEIN P53; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CARDIOTOXICITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK REDUCTION; SOFT TISSUE SARCOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; AGED; CLINICAL TRIAL; DNA REPAIR; MIDDLE AGED; MORTALITY; PROGNOSIS; SARCOMA;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DNA REPAIR; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; TETRAHYDROISOQUINOLINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84976463182     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.3329     Document Type: Article

References (40)

1. Blackledge G, van Oosterom A, Mouridsen H, et al: Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 26:139-141, 1990
2. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
3. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
4. Maurel J, López-Pousa A, de Las Peñas R, et al: Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 27:1893-1898, 2009
5. Le Cesne A, Blay JY, Judson I, et al: Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576-584, 2005
6. Demetri GD, Chawla SP, von Mehren M, et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188-4196, 2009
7. Meco D, Colombo T, Ubezio P, et al: Effective combination of ET-743 and doxorubicin in sarcoma: Preclinical studies. Cancer Chemother Pharmacol 52: 131-138, 2003
8. Takahashi N, Li WW, Banerjee D, et al: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251-3257, 2001
9. Blay JY, von Mehren M, Samuels BL, et al: Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 14:6656-6662, 2008
10. von Mehren M, Schilder RJ, Cheng JD, et al: A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 19:1802-1809, 2008
11. Italiano A, Laurand A, Laroche A, et al: ERCC5/ XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 117:3445-3456, 2011
12. Martínez-Serra J, Maffiotte E, Martín J, et al: Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action. Eur J Pharmacol 658:57-64, 2011
13. Grosso F, Dileo P, Sanfilippo R, et al: Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 42:1484-1490, 2006
14. Lorigan P, Verweij J, Papai Z, et al: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25:3144-3150, 2007
15. Bubendorf L, Nocito A, Moch H, et al: Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72-79, 2001
16. Judson I, Verweij J, Gelderblom H, et al: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol 15:415-423, 2014
17. Tap W, Jones R, Chmielowsk B, et al: A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human antiplatelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). J Clin Oncol 33:2015 (suppl; abstr 10501)
18. Ryan C, Schoffski P, Merimsky O, et al: PICASSO 3: A phase III international, randomized, double-blind, placebo-controlled study of doxorubicin (dox) plus palifosfamide (pali) vs. dox plus placebo for patients (pts) in first-line for metastatic soft tissue sarcoma (mSTS). Eur J Cancer 49:S876, 2013 (suppl 2; abstr 3802)
19. Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61, 2007
20. Apetoh L, Ghiringhelli F, Tesniere A, et al: Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059, 2007
21. Ma Y, Adjemian S, Mattarollo SR, et al: Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38:729-741, 2013
22. Germano G, Frapolli R, Belgiovine C, et al: Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23:249-262, 2013
23. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al: Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 117:1049-1054, 2011
24. Poulaki V, Mitsiades CS, Mitsiades N: The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Updat 4:233-242, 2001
25. Gordon N, Arndt CA, Hawkins DS, et al: Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27:611-615, 2005
26. Rao-Bindal K, Koshkina NV, Stewart J, et al: The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 13:411-422, 2013
27. Koshkina NV, Khanna C, Mendoza A, et al: Fasnegative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 5:991-999, 2007
28. Würl P, Taubert H, Meye A, et al: Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: A multivariate analysis of five antibodies. J Cancer Res Clin Oncol 123:502-508, 1997
29. Taubert H, Meye A, Würl P: Soft tissue sarcomas and p53 mutations. Mol Med 4:365-372, 1998
30. Drobnjak M, Latres E, Pollack D, et al: Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult softtissue sarcomas. J Natl Cancer Inst 86:549-554, 1994
31. Hieken TJ, Das Gupta TK: Mutant p53 expression: A marker of diminished survival in welldifferentiated soft tissue sarcoma. Clin Cancer Res 2: 1391-1395, 1996
32. Das P, Kotilingam D, Korchin B, et al: High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 109:2323-2333, 2007
33. Müller M, Wilder S, Bannasch D, et al: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045, 1998
34. Pautier P, Floquet A, Chevreau C, et al: Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): A non-randomised, multicentre, phase 2 trial. Lancet Oncol 16:457-464, 2015
35. Hensley ML, Blessing JA, Mannel R, et al: Fixed-dose rate gemcitabine plus docetaxel as firstline therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329-334, 2008
36. Pautier P, Floquet A, Penel N, et al: Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 17: 1213-1220, 2012
37. Le Cesne A, Cresta S, Maki RG, et al: A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer 48:3036-3044, 2012
38. Blay JY, Leahy MG, Nguyen BB, et al: Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapyasfirst-line therapy in translocation-related sarcomas. Eur J Cancer 50: 1137-1147, 2014
39. Le Cesne A, Blay JY, Domont J, et al: Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): A randomised phase 2 trial. Lancet Oncol 16:312-319, 2015
40. Buyse M, Sargent DJ, Grothey A, et al: Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7:309-317, 2010